Literature DB >> 15273731

Induction of centrosome amplification and chromosome instability in p53-null cells by transient exposure to subtoxic levels of S-phase-targeting anticancer drugs.

Richard A Bennett1, Hideki Izumi, Kenji Fukasawa.   

Abstract

Chromosome instability (CIN) is one of the most important phenotypes in tumor progression, introducing multiple mutations required for acquisition of further malignant characteristics. Abnormal amplification of centrosomes, which is frequently observed in human cancer, has been shown to contribute to CIN by increasing the frequency of mitotic defects. Here, we show that transient exposure to subtoxic concentrations of commonly used anticancer drugs that target DNA synthesis induces centrosome amplification in cells lacking p53 tumor suppressor protein, by allowing continuous centrosome duplication in the absence of DNA synthesis. When these cells are released from cell cycle arrest by removal of drugs, cells suffer extensive destabilization of chromosomes. Considering that p53 is the most frequently mutated gene in human cancer and that CIN is known to be associated with acquisition of malignant phenotypes, our observations may explain why recurrent tumors, after chemotherapy, often exhibit more malignant characteristics than the original tumors. The tumor cells that are exposed to subtoxic levels of DNA synthesis-targeting drugs will be arrested and undergo centrosome amplification. Upon cessation of chemotherapy, these cells will re-enter cell cycling, and experience extensive CIN due to the presence of amplified centrosomes. This in turn promotes generation of tumor cells equipped with further malignant characteristics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15273731     DOI: 10.1038/sj.onc.1207561

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  Molecular dissection of the centrosome overduplication pathway in S-phase-arrested cells.

Authors:  Suzanna L Prosser; Kees R Straatman; Andrew M Fry
Journal:  Mol Cell Biol       Date:  2009-01-12       Impact factor: 4.272

2.  Depletion of licensing inhibitor geminin causes centrosome overduplication and mitotic defects.

Authors:  Kiku-e K Tachibana; Michael A Gonzalez; Giulia Guarguaglini; Erich A Nigg; Ronald A Laskey
Journal:  EMBO Rep       Date:  2005-09-23       Impact factor: 8.807

3.  Krüppel-like factor 4 prevents centrosome amplification following gamma-irradiation-induced DNA damage.

Authors:  Hong S Yoon; Amr M Ghaleb; Mandayam O Nandan; Irfan M Hisamuddin; William Brian Dalton; Vincent W Yang
Journal:  Oncogene       Date:  2005-06-09       Impact factor: 9.867

Review 4.  Turning the headlights on novel cancer biomarkers: Inspection of mechanics underlying intratumor heterogeneity.

Authors:  Michelle McBride; Padmashree C G Rida; Ritu Aneja
Journal:  Mol Aspects Med       Date:  2015-05-27

5.  Roles of cyclins A and E in induction of centrosome amplification in p53-compromised cells.

Authors:  K Hanashiro; M Kanai; Y Geng; P Sicinski; K Fukasawa
Journal:  Oncogene       Date:  2008-05-19       Impact factor: 9.867

Review 6.  Centrosome amplification, chromosomal instability and cancer: mechanistic, clinical and therapeutic issues.

Authors:  Marco Raffaele Cosenza; Alwin Krämer
Journal:  Chromosome Res       Date:  2016-01       Impact factor: 5.239

7.  Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts.

Authors:  A B D'Assoro; R Busby; I D Acu; C Quatraro; M M Reinholz; D J Farrugia; M A Schroeder; C Allen; F Stivala; E Galanis; J L Salisbury
Journal:  Oncogene       Date:  2008-02-11       Impact factor: 9.867

8.  Chloroquine alleviates etoposide-induced centrosome amplification by inhibiting CDK2 in adrenocortical tumor cells.

Authors:  T-Y Chen; J-S Syu; T-C Lin; H-L Cheng; F-L Lu; C-Y Wang
Journal:  Oncogenesis       Date:  2015-12-21       Impact factor: 7.485

9.  p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells.

Authors:  Kimberly M McDermott; Jianmin Zhang; Charles R Holst; B Krystyna Kozakiewicz; Veena Singla; Thea D Tlsty
Journal:  PLoS Biol       Date:  2006-02-14       Impact factor: 8.029

10.  Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine.

Authors:  A C Dudley; S-C Shih; A R Cliffe; K Hida; M Klagsbrun
Journal:  Br J Cancer       Date:  2008-07-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.